This article describes a mechanism through which CD4+ T cells can eradicate MHC-deficient tumours that escape direct CD8+ T cell targeting and thereby complement the activity of CD8+ T cells and natural killer cells to advance cancer immunotherapies. The gene discussed is CD8A; the disease is cancer.